Currently in preclinical stage
Toxicology tests expected to be conducted soon
Phase I/II seen beginning in 15-20 months
THSTI will conduct animal challenge studies using model developed for SARS-CoV-2, CEPI will aid with primate challenge studies.
CEPI’s funds will help it through Phase I and Phase II clinical trials
If predetermined parameters on immunogenicity and safety are met, CEPI might consider allocating more funds for next steps to commercialization
The partners “hope to offer this vaccine in the next two to three years,” THSTI executive director Pramod Garg said

CEPI Partners Panacea, THSTI For Pan Beta Coronavirus Vaccines

Panacea’s Dengue, Pneumococcal Vaccines On Track